Two whistleblowers have adequately alleged that Amedisys Inc. violated the False Claims Act by improperly billing Medicare and other federal health-care programs for home health services, a New York ...

UnitedHealth Group and Amedisys dropped their request to dismiss a government antitrust lawsuit over the insurer's proposed $3.3 billion acquisition of the home health provider. The companies said ...

BATON ROUGE, La., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice and high-acuity care services, has recognized 47 employees with the ...

In a report released on January 29, Whit Mayo from Leerink Partners reiterated a Hold rating on Amedisys (AMED – Research Report), with a price target of $101.00. Whit Mayo has given his Hold ...

Amedisys, Inc. (NASDAQ:AMED – Free Report) – Research analysts at Leerink Partnrs cut their FY2024 earnings estimates for Amedisys in a note issued to investors on Wednesday, January 29th.

BATON ROUGE, La., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice and high-acuity care services, has recognized 47 employees with the ...

UnitedHealth Group says the Justice Department’ s antitrust challenge to its proposed $3.3 billion purchase of Amedisys is wrong on the merits and threatens to deprive consumers of benefits from ...

The cure rate for [diffuse midline glioma] is less than 1%, and the median overall survival is nine to 11 months,” said Dr.